Amoxicillin and Clavulanate Potassium Tablet for GMP Medicine

Product Details
Customization: Available
Application: Internal Medicine
Usage Mode: For oral administration
Still deciding? Get samples of US$ 0/Piece
Request Sample
Manufacturer/Factory, Trading Company

360° Virtual Tour

Diamond Member Since 2015

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

Years of Export Experience
The export experience of the supplier is more than 10 years
High Repeat Buyers Choice
More than 50% of buyers repeatedly choose the supplier
Importers and Exporters
The supplier has import and export rights
Management Certification
The supplier has quality management system certification, including:
ISO9001:2015 certificate
ISO45001:2018 certificate
ISO14001
to see all verified strength labels (20)
  • Amoxicillin and Clavulanate Potassium Tablet for GMP Medicine
  • Amoxicillin and Clavulanate Potassium Tablet for GMP Medicine
  • Amoxicillin and Clavulanate Potassium Tablet for GMP Medicine
  • Amoxicillin and Clavulanate Potassium Tablet for GMP Medicine
  • Amoxicillin and Clavulanate Potassium Tablet for GMP Medicine
  • Amoxicillin and Clavulanate Potassium Tablet for GMP Medicine
Find Similar Products

Basic Info.

Model NO.
AMC12061-04
Suitable for
Elderly, Adult
State
Solid
Shape
Tablet
Type
Organic Chemicals
Pharmaceutical Technology
Chemical Synthesis
Transport Package
2X7tablets/Box
Specification
625mg / 1g
Trademark
OEM
Origin
China
HS Code
3004101200
Production Capacity
300000boxes/Month

Product Description

Amoxicillin and Clavulanate Potassium Tablet for GMP Medicine
Composition:

Amoxi and Clavulanate Potassium 1g Film Coated Tablet: Each film coated tablet contacines Amoxi Trihydrate USP equivalent to Amoxi 875mg and Clavulanate Potassium USP equivalent to Clavalanic acid 125mg.

Properties:

Amoxiand Clavulanate Potassium is an oral antibacterial combination consiating of the semi synthetic broad-spectrum antibiotic Amoxi and the beta-lactamase enzyme inhibitor clavulanic acid, which protects amoxi from destruction and subsequent loss of antibacterial activity by the beta-lactamase enzyme produced by many gram-negative and gram-positive vacteria.

This conbination extends the spectrum of amoxi to include a wider range of organisms, including many resistant to other beta-lactam antibiotics. Amoxi and clavulanic acid are well absorbed from the gastrointestinal tract following oral administration of Amoxi and Clavulanate Potassium.

Amoxi and Clavulanate Potassium is bacterial against a wide range of beta-lactamase and non-beta-lactamase producing organisms including:

Gram-positive: and Gram-negative

Indications:

Amoxi and Clavulanate Potassium is indicated for treatment of the following bacterial inlections due to susceptible organisms:

-Upper respiratory tract infection (including ENT) , e.g. tonsillitis, sinusitis, otitis media;

-Lower respiratory tract infections, e.g. actue and chronic bronchitis, lobar and bronchopneumonia.

-Gentio-urinary tract infection, e.g. cystitis, urethritis, pyelonephritis, pelvic infection, chancroid, gonorrhoea.

-Skin and soft tissue infection, e.g. boils, abscesses, cellulitis, animal bites, wound infections.

-Bone and joint infections, e.g. osteomyelitis

Dosage and Administration:

Amoxi and Clavulanate Potassiummay be administrated without regards to meals. However, to munimize potential pastrointestinal intolerance, administer at the start of a meal.

Adults and Children over 12 years:
 

Mild-Moderate infections: One Amoxiand Clavulanate Potassium 375mg tablet every 8 hours.
Severe infections:  One Amoxi and Clavulanate Potassium 625mg tablet every 8 hours or one 1g tablet every 12 hours.
Severe dental infections( but not generally first-line): one KONN  One Amoxi and Clavulanate Potassium 375mg tablet every 8hour lor 5 days.

Contraindications:

Amoxi and Clavulanate Potassium should not be administrated to patients hypersensitive to penicillins, cephalosporins and other beta-lactams, It is also contraindicated in patients with a previous history of Amoxi and Clavulanate acid or penicillin-associated jaundice or hepatic dysfunction.

Use in Pregnancy and lactation:

As with all mediciens, use should be avoided in pregnancy, especially during the first trimester, unless considered essential by the physician.

Amoxi and Clavulanate Potassium may be administrated during the period of lactation.

With the exception of the risk of sensitization, associated with excretion of trace amounts in the breast milk, there are no significant effects to the infants.

Side effects:

Amoxi and Clavulanate Potassium is well tolerated. Side effects, as with amoxi, are uncommon and mainly of mild and transitory nature. The reported adverse effects include diarrhoea, nausea, vomiting, antibiotic-associated colitis, and candidiasis have been reported. Hepatitis and cholestatic jaundice have been reported rarely.

Drug interaction:

Prolongation of bleeding time and prothrombin time have been reported in some patients receving amoxi clavulanic acid. Amoxi and Clavulanate Potassium should be used with care in patients on anti-coagulant therapy,in common with other broad-spectrum antibiotics, Amoxi and Clavulanate Potassium may reduce the efficacy of oral contraceptives and patients should be wamed accordingly.

Storage:

Store at room temperature below 30c, in a dry place, protected from light.

Amoxicillin and Clavulanate Potassium Tablet for GMP MedicineAmoxicillin and Clavulanate Potassium Tablet for GMP MedicineAmoxicillin and Clavulanate Potassium Tablet for GMP MedicineAmoxicillin and Clavulanate Potassium Tablet for GMP MedicineAmoxicillin and Clavulanate Potassium Tablet for GMP MedicineAmoxicillin and Clavulanate Potassium Tablet for GMP Medicine

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier